Preclinical Evaluation of A Potent 2nd Generation Small-Molecule Hsp90 Inhibitor STA-9090 In Hematological Cell Lines

被引：0
|
作者：
Ying, Weiwen [1 ]
Proia, David [1 ]
He, Suqin [1 ]
Sang, Jim [1 ]
Foley, Kevin [1 ]
Du, Zhenjian [1 ]
Blackman, Ronald K. [1 ]
Wada, Yumiko [1 ]
Sun, Lijun [1 ]
Koya, Keizo [1 ]
机构：
[1] Synta Pharmaceut, Lexington, MA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1194 / 1194
页数：1
相关论文
共 33 条
  • [21] BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models
    Lundgren, Karen
    Zhang, Hong
    Kamal, Adeela
    Lough, Rachel
    Timple, Noelito
    Sensintaffar, John
    Busch, David
    Yang, Cindy
    Neely, Laura
    Khan, Samina
    Hong, Kevin
    Kasibhatla, Srinivas
    Boehm, Marcus
    Burrows, Francis
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3485S - 3485S
  • [22] Preclinical efficacy of STA-12-8666, an HSP90 inhibitor-targeted SN-38 conjugate, in small cell lung cancer (SCLC).
    Boumber, Yanis
    Gaponova, Anna
    Nikonova, Anna S.
    Deneka, Alexander
    Kudinov, Alexander
    Egleston, Brian L.
    Duncan, James S.
    Duncan, Kelly
    Borghaei, Hossein
    Mehra, Ranee
    Proia, David A.
    Golemis, Erica
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] The Novel HSP90 Inhibitor-SN-38 Conjugate (STA-12-8666), Is Highly Active in Preclinical Models of Small Cell Lung Cancer (SCLC)
    Boumber, Yanis
    Gaponova, Anna
    Nikonova, Anna
    Deneka, Alexander
    Kudinov, Alexander
    Kopp, Meghan
    Egleston, Brian L.
    Litwin, Sam
    Duncan, James S.
    Duncan, Kelly
    Borghaei, Hossein
    Mehra, Ranee
    Proia, David
    Golemis, Erica
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S399 - S399
  • [24] Preclinical testing demonstrates strong activity of STA-12-8666, an HSP90 inhibitor-SN-38 conjugate, in small cell lung cancer (SCLC)
    Gaponova, Anna
    Nikonova, A. S.
    Deneka, A.
    Egleston, B. L.
    Litwin, S.
    Duncan, J. S.
    Duncan, K.
    Borghaei, H.
    Mehra, R.
    Proia, D. A.
    Boumber, Y.
    Golemis, Erica
    CANCER RESEARCH, 2015, 75
  • [25] Biologic effects of NVP-AUY922, a novel small molecule inhibitor of HSP90 in human colon and gastric cancer cell lines
    Wainberg, Zev
    Anghel, Adrian
    Desai, Amrita
    Adhani, Shahriar
    Safran, Brent
    Hecht, J.
    Jensen, Michael
    Quadt, Cornelia
    Slamon, Dennis
    Finn, Richard
    CANCER RESEARCH, 2009, 69
  • [26] Preclinical Testing Demonstrates Striking Efficacy of STA-12-8666, an Hsp90 Inhibitor-Targeted SN-38 Conjugate, in Small Cell Lung Cancer
    Boumber, Y.
    Gaponova, A.
    Nikonova, A. S.
    Deneka, A.
    Kudinov, A.
    Chikwem, A.
    Egleston, B. L.
    Litwin, S.
    Duncan, J. S.
    Duncan, K.
    Borghaei, H.
    Mehra, R.
    Proia, D.
    Golemis, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S64 - S65
  • [27] BIIB021, an orally available and small-molecule inhibitor of HSP90, activates intrinsic apoptotic pathway in human cervical adenocarcinoma cell line (HeLa)
    Guven, C. M.
    Ozgur, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (15) : 7299 - 7308
  • [28] Gephyromycin C, a novel small-molecule inhibitor of heat shock protein Hsp90, induces G2/M cell cycle arrest and apoptosis in PC3 cells in vitro
    Ding, Wan-jing
    Ji, Yuan-yuan
    Jiang, Yong-jun
    Ying, Wei-jia
    Fang, Zhang-yun
    Gao, Ting-ting
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 531 (03) : 377 - 382
  • [29] BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows potent anti-tumor activity as a single agent and in combination with standard of care therapies in preclinical tumor models
    Lundgren, K.
    Timple, N.
    Ibanez, G.
    Yang, C.
    Neely, L.
    Kamal, A.
    Hong, K.
    Zhang, H.
    EJC SUPPLEMENTS, 2008, 6 (12): : 50 - 50
  • [30] IPI-504, a selective inhibitor of Hsp90, exhibits potent antitumor activity against Her2 positive, Herceptin-sensitive and refractory cell lines
    Leow, Ching Ching
    Coffman, Karen
    Chesebrough, Ion
    Mao, Shenlan
    Fazenbaker, Christine
    Weng, David
    Gooya, John
    Porter, James
    Coats, Steve
    Jallal, Bahija
    Jackson, Dowdy
    Chang, Yong S.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3504S - 3504S
1234